Updated Visitor Restriction Policy

Effective Monday, April 5, 2021, Rutland Regional has updated the visitation policy to allow for limited visitation. Please read the full policy before coming to the hospital or one of the clinics:

Visitor Restriction Policy

Skip to Content

Breast-Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy

Objective

SWOG S1007 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and Her-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less

The purpose of this study is to find out if the Oncotype DX® Recurrence Score can help decide whether patients should receive chemotherapy or not.  This study is being done in patients with lower Recurrence Scores (25 or less).

Recurrence Score: The Oncotype DX® is a test that looks at multiple genes related to breast cancer. The combination of the test results produces a score that is useful in guiding treatment choices for patients with node-negative breast cancer. The higher the score is, the more likely that the patient’s breast cancer will come back after surgery.


Contact
Rebecca Denofer, RN, OCN at 802-747-1692
or rdenofer@rrmc.org

RUTLAND REGIONAL MEDICAL CENTER160 Allen Street, Rutland, VT 05701802.775.7111

© 2021 Rutland Medical Center